US FDA approves Johnson & Johnson's blood cancer therapy; check details
Though multiple myeloma is rare compared to breast or prostate cancer, it is a common type of blood cancer, which develops in the bone marrow and can spread throughout the body.
FollowJohnson & Johnson's on Tuesday said that the US Food and Drug Administration (FDA) approved the therapy for treating a type of multiple myeloma, giving another treatment option to patients with the incurable blood cancer.
J&J's teclistamab, also known as Tecvayli, is approved for treating adults with multiple myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of therapies.
Also read:Â Amou Haji, 'world's dirtiest man', dies at 94; he had his first wash few months ago
The therapy, which will be available on or around November 4, is reportedly said to list price of $39,500 per month, with the overall pricing ranging between $355,000 and $395,000 for a nine to 10 month course.
Tecvayli, a bispecific antibody, is reportedly engineered to redirect the body's immune system to recognize and kill cancer cells. It is also the first drug of its class to be approved for multiple myeloma.
According to reports, the approval comes with a boxed warning for cytokine release syndrome, a condition where the immune system reacts more aggressively than it should.
Also read: Woman claims L'Oréal hair straightening products caused uterine cancer: See details
While there are other approved therapies for treating multiple myeloma such as Abecma from rival Bristol-Myers Squibb and GSK Plc's Blenrep, many patients see a relapse after stopping treatment, making it an area of significant unmet need that drugmakers can tap into.
In August, J&J's treatment received conditional approval from the European drug regulator.
Though multiple myeloma is rare compared to breast or prostate cancer, it is a common type of blood cancer, which develops in the bone marrow and can spread throughout the body.
Also read: Climate activists throw mashed potatoes on Monet’s Les Meules painting in Germany | Watch
It is reportedly said that the cancer is typically diagnosed in people aged between 65 and 74 and affects more men than women.
According to the American Cancer Society's estimates, close to 35,000 new cases of multiple myeloma are likely to be diagnosed in the United States this year.
